Ironwood Pharmaceuticals, Inc. (IRWD)
4.08
+0.11
(+2.77%)
USD |
NASDAQ |
Sep 11, 16:00
4.075
0.00 (0.00%)
After-Hours: 20:00
Ironwood Pharmaceuticals Enterprise Value : 991.92M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 991.92M |
| September 10, 2026 | 973.74M |
| September 09, 2026 | 990.27M |
| September 08, 2026 | 1.007B |
| September 04, 2026 | 1.022B |
| September 03, 2026 | 1.027B |
| September 02, 2026 | 1.046B |
| September 01, 2026 | 1.023B |
| August 31, 2026 | 1.020B |
| August 28, 2026 | 1.000B |
| August 27, 2026 | 1.018B |
| August 26, 2026 | 1.027B |
| August 25, 2026 | 1.043B |
| August 24, 2026 | 1.000B |
| August 21, 2026 | 1.027B |
| August 20, 2026 | 1.002B |
| August 19, 2026 | 1.038B |
| August 18, 2026 | 1.030B |
| August 17, 2026 | 1.038B |
| August 14, 2026 | 1.030B |
| August 13, 2026 | 991.92M |
| August 12, 2026 | 1.032B |
| August 11, 2026 | 1.028B |
| August 10, 2026 | 986.96M |
| August 07, 2026 | 1.032B |
| Date | Value |
|---|---|
| August 06, 2026 | 1.022B |
| August 05, 2026 | 1.003B |
| August 04, 2026 | 1.030B |
| August 03, 2026 | 1.048B |
| July 31, 2026 | 1.017B |
| July 30, 2026 | 934.08M |
| July 29, 2026 | 905.99M |
| July 28, 2026 | 945.65M |
| July 27, 2026 | 963.83M |
| July 24, 2026 | 930.78M |
| July 23, 2026 | 944.00M |
| July 22, 2026 | 958.87M |
| July 21, 2026 | 963.83M |
| July 20, 2026 | 953.91M |
| July 17, 2026 | 955.56M |
| July 16, 2026 | 957.22M |
| July 15, 2026 | 978.70M |
| July 14, 2026 | 975.39M |
| July 13, 2026 | 1.013B |
| July 10, 2026 | 1.056B |
| July 09, 2026 | 1.089B |
| July 08, 2026 | 1.106B |
| July 07, 2026 | 1.056B |
| July 06, 2026 | 1.041B |
| July 02, 2026 | 1.033B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Rigel Pharmaceuticals, Inc. | 825.83M |
| Marker Therapeutics, Inc. | 7.252M |
| Theriva Biologics, Inc. | 3.579M |
| AbbVie, Inc. | 518.65B |
| Capricor Therapeutics, Inc. | 339.48M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 51.29M |
| Revenue (Quarterly) | 113.04M |
| Total Expenses (Quarterly) | 61.75M |
| EPS Diluted (Quarterly) | 0.3068 |
| Gross Profit Margin (Quarterly) | 99.60% |
| Profit Margin (Quarterly) | 45.37% |
| Earnings Yield | 18.79% |
| Operating Earnings Yield | 34.34% |
| Normalized Earnings Yield | 18.98 |